Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 510-517

  Renzi, Paolo M ^a   Howard, Lisa A ^b   Ortega, Hector G ^c   Ahmad, Faiz F ^c   Chapman, Kenneth R ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Asthma; Bronchodilator; Controller; Rescue medication

Indexed keywords

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE; ANDROSTANE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUTICASONE; SALBUTAMOL; SALMETEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTICENTER STUDY; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CANADA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CANADA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77349099670     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.10.025     Document Type: Article

References (32)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available from (2007). http://www.ginasthma.org
2. National Heart Lung and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma (2007), US Department of Health and Human Services, Bethesda, MD
3. Lemiere C., Bai T., Balter M., et al. Adult asthma consensus guidelines update 2003. Can Respir J 11 (2004) 9A-18A
4. Chapman K.R., Boulet L.P., Rea R.M., et al. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 31 (2008) 320-325
5. Fitzgerald J.M., Boulet L.P., McIvor R.A., et al. Asthma control in Canada remains suboptimal: The Reality of Asthma Control (TRAC) study. Can Respir J 13 (2006) 253-259
6. Rabe K.F., Vermeire P.A., Soriano J.B., et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 16 (2000) 802-807
7. Matz J, Emmett A, Rickard K, et al. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 107:783-789.
8. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
9. LaForce C.F., Pearlman D.S., Ruff M.E., et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann Allergy Asthma Immunol 85 (2000) 407-415
10. Pauwels R.A., Löfdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
11. Bateman E.D., Bousquet J., Keech M.L., Busse W.W., Clark T.J., and Pedersen S.E. The correlation between asthma control and health status: the GOAL study. Eur Respir J 29 (2007) 56-62
12. Lundbäck B., Rönmark E., Lindberg A., et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 100 (2006) 2-10
13. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 170 (2004) 836-844
14. Murray J., Rosenthal R., Somerville L., et al. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Ann Allergy Asthma Immunol 93 (2004) 351-359
15. Strand A.M., and Luckow A. Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir Med 98 (2004) 1008-1015
16. Nelson H.S., Wolfe J.D., Gross G., et al. Efficacy and safety of fluticasone propionate 44 μg/salmeterol 21 μg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. Ann Allergy Asthma Immunol 91 (2003) 263-269
17. Postma D.S., Kerstjens H.A., and ten Hacken N.H. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 203-215
18. Stoloff S.W., Stempel D.A., Meyer J., et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 113 (2004) 245-251
19. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
20. Teeter J.G., and Bleecker E.R. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest 113 (1998) 272-277
21. Zeiger R.S., Baker J.W., Kaplan M.S., Pearlman D.S., et al. Variability of symptoms in mild persistent asthma: baseline data from the MIAMI study. Respir Med 98 (2004) 898-905
22. Juniper E.F., Wisniewski M.E., Cox F.M., et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 23 (2004) 287-291
23. Wolfenden L.L., Diette G.B., Krishnan J.A., et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med 163 (2003) 231-236
24. Carranza Rosenzweig J.R., Edwards L., Lincourt W., et al. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 98 (2004) 1157-1165
25. Boulet L.P., Phillips R., O'Byrne P., and Becker A. Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can Respir J 9 (2002) 417-423
26. Demoly P., Crestani B., Leroyer C., et al. Control and exacerbation of asthma: a survey of more than 3000 French physicians. Allergy 59 (2004) 920-926
27. Miller M., Johnson C., Miller D., et al. Severity assessment in asthma: an evolving concept. J Allergy Clin Immunol 116 (2005) 990-995
28. Vervloet D., Williams A.E., Lloyd A., et al. Costs of managing asthma as defined by a derived Asthma Control Test™ score in seven European countries. Eur Respir Rev 15 (2006) 17-23
29. Baumgarten C., Geldszus R., Behre U., et al. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023). Eur J Med Res 7 (2002) 1-7
30. Robertson C.F., Rubinfeld A.R., and Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 13 (1992) 95-100
31. Seung S.J., and Mittmann N. Urgent care costs of uncontrolled asthma in Canada. Can Respir J 2005 12 (2004) 435-436
32. Boushey H.A., Sorkness C.A., King T.S., et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 352 (2005) 1519-1528